Needham Reiterates Buy Rating on CRISPR Therapeutics AG (CRSP)

Market Context

CRISPR Therapeutics AG operates in the Healthcare sector. The stock currently trades at $49.94 with a market capitalization of $5.1B. The stock has declined 11.7% over the past 52 weeks.

Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CRISPR Therapeutics AG.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for CRISPR Therapeutics AG

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 03, 2026	Needham	Buy	N/A
Oct 15, 2026	UBS	Neutral	N/A
Aug 31, 2026	Citizens	Market Outperform	N/A
Aug 31, 2026	Needham	Buy	N/A
Aug 25, 2026	Citizens	Market Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View CRSP Stock Page